The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis
| dc.contributor.author | Arnaiz, J. A. | |
| dc.contributor.author | Rodrigues Silva, C. | |
| dc.contributor.author | Mezquida, G. | |
| dc.contributor.author | Bobes, Julio | |
| dc.contributor.author | García-Portilla González, María Paz | |
| dc.contributor.author | PEPs Group | |
| dc.date.accessioned | 2021-06-01T09:39:17Z | |
| dc.date.available | 2021-06-01T09:39:17Z | |
| dc.date.issued | 2021 | |
| dc.identifier.citation | Psychopharmacology, 238, p. 665-676 (2021); doi:10.1007/s00213-020-05715-5 | |
| dc.identifier.issn | 0033-3158 | |
| dc.identifier.uri | http://hdl.handle.net/10651/58407 | |
| dc.description.sponsorship | This study was supported by the Ministerio de Economía y Competitividad (Ref. ISCIII: PI 080208, PI0/00,283 and PI14/00,612)—Instituto de Salud Carlos III—Fondo Europeo de Desarrollo Regional (FEDER)-Unión Europea; the Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM); and by the CERCA Programme / the Government of Catalonia, Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2017SGR1562; 2017SGR1355; 2017SGR881). Dr. Vieta thanks the support of the Spanish Ministry of Science, Innovation and Universities (PI15/00283) integrated into the Plan Nacional de I+D+I y cofinanciado por el ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER); CIBERSAM; and the Comissionat per a Universitats i Recerca del DIUE de la Generalitat de Catalunya to the Bipolar Disorders Group (2017 SGR 1365) and the project SLT006/17/00357, from PERIS 2016-2020 (Departament de Salut). CERCA Programme/Generalitat de Catalunya. | |
| dc.description.statementofresponsibility | Arnaiz, J.A., Rodrigues-Silva, C., Mezquida, G., Amoretti, S., Cuesta, M.J., Fraguas, D., Lobo, A., González-Pinto, A., Díaz-Caneja, M.C., Corripio, I., Vieta, E., Baeza, I., Mané, A., García-Rizo, C., Bioque, M., Saiz, J., Bernardo, M., Mas, S., Torra, M., Llerena, A., Anmella, G., Colomer, L., Moreno, C., Durán-Cutilla, M., Alonso Solís, A., Grasa, E., Lopez, P., García, S., De-la-Cámara, C., Aragón, Z., Saz, P., Moltó, M.D., Hernandez Viadel, M., Casanovas, F., SanAgustin, D., Castro-Fornieles, J., de la Serna, E., Contreras, F., Saiz, C., Bobes, J., García-Portilla, M.P., Gutierrez Fraile, M., Zabala Rabadán, A., Rodríguez-Jimenez, R., Fares-Otero, N.E., Usall, J., Butjosa, A., Sarró, S., Pomarol-Clotet, E., Ibañez, A., Ribeiro, M., Balanzá-Martínez, V. | |
| dc.format.extent | p. 665-676 | |
| dc.language.iso | eng | |
| dc.relation.ispartof | Psychopharmacology | |
| dc.rights | © Springer-Verlag GmbH Germany, part of Springer Nature 2020 | |
| dc.source | Scopus | |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85097593779&doi=10.1007%2fs00213-020-05715-5&partnerID=40&md5=d49788ee9596c2a0fd27780288563b20 | |
| dc.title | The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.doi | 10.1007/s00213-020-05715-5 | |
| dc.type.dcmi | text | |
| dc.relation.projectID | MINECO/PI 080208 | |
| dc.relation.projectID | MINECO/PI0/00,283 | |
| dc.relation.projectID | MINECO/PI14/00,612 | |
| dc.relation.projectID | FEDER/PI15/00283 | |
| dc.relation.publisherversion | http://dx.doi.org/10.1007/s00213-020-05715-5 |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||
This item appears in the following Collection(s)
-
Artículos [33264]